CA3107037A1 - Improved rsv passive and active vaccines - Google Patents

Improved rsv passive and active vaccines Download PDF

Info

Publication number
CA3107037A1
CA3107037A1 CA3107037A CA3107037A CA3107037A1 CA 3107037 A1 CA3107037 A1 CA 3107037A1 CA 3107037 A CA3107037 A CA 3107037A CA 3107037 A CA3107037 A CA 3107037A CA 3107037 A1 CA3107037 A1 CA 3107037A1
Authority
CA
Canada
Prior art keywords
rsv
seq
protein
mab
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3107037A
Other languages
English (en)
French (fr)
Inventor
Milton J. Friedman
Lawrence M. Kauvar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of CA3107037A1 publication Critical patent/CA3107037A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA3107037A 2018-08-08 2019-08-08 Improved rsv passive and active vaccines Pending CA3107037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862716184P 2018-08-08 2018-08-08
US62/716,184 2018-08-08
PCT/US2019/045775 WO2020033742A1 (en) 2018-08-08 2019-08-08 Improved rsv passive and active vaccines

Publications (1)

Publication Number Publication Date
CA3107037A1 true CA3107037A1 (en) 2020-02-13

Family

ID=69415133

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3107037A Pending CA3107037A1 (en) 2018-08-08 2019-08-08 Improved rsv passive and active vaccines

Country Status (5)

Country Link
US (2) US12246063B2 (https=)
EP (1) EP3833677A4 (https=)
JP (1) JP2021534239A (https=)
CA (1) CA3107037A1 (https=)
WO (1) WO2020033742A1 (https=)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2949031A1 (de) * 1978-12-15 1980-07-17 Sandoz Ag Vakzine
EP0777685B1 (en) * 1994-08-25 1999-04-14 Stichting Instituut voor Dierhouderij en Diergezondheid Antigenic peptides derived from the g protein of rsv for type- and subtype-specific diagnosis of respiratory syncytial virus (rsv) infection
AUPO026596A0 (en) 1996-06-05 1996-06-27 Biomolecular Research Institute Limited Viral peptide
CA2426312C (en) 2000-10-18 2014-01-14 Ralph A. Tripp Compositions and methods for modulating rsv infection and immunity
US6818216B2 (en) 2000-11-28 2004-11-16 Medimmune, Inc. Anti-RSV antibodies
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7368537B2 (en) 2003-07-15 2008-05-06 Id Biomedical Corporation Of Quebec Subunit vaccine against respiratory syncytial virus infection
WO2009055711A2 (en) * 2007-10-25 2009-04-30 Trellis Bioscience, Inc. Anti-rsv g protein antibodies
US8846056B2 (en) 2009-08-04 2014-09-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control Anti-RSV immunogens and methods of immunization
CN106008716B (zh) 2010-07-07 2019-08-13 人工细胞科技公司 呼吸道合胞病毒抗原组合物和方法
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA035846B1 (ru) * 2013-04-15 2020-08-20 Янссен Вэксинс Энд Превеншн Б.В. Антитела человека, связывающиеся с g-белком rsv
JO3555B1 (ar) * 2015-10-29 2020-07-05 Merck Sharp & Dohme جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
WO2017132550A1 (en) 2016-01-28 2017-08-03 The Brigham And Women's Hospital, Inc. Detection of an antibody against a pathogen
CA3079604A1 (en) 2017-10-13 2019-04-18 Trellis Bioscience, Llc Conformational epitopes in respiratory syncytial virus g protein central conserved region
US20200033307A1 (en) 2018-07-25 2020-01-30 Honeywell International Inc. Method of determining an amount of water in a sample using a derivative of imidazole and a hydrogen halide donor

Also Published As

Publication number Publication date
EP3833677A1 (en) 2021-06-16
JP2021534239A (ja) 2021-12-09
EP3833677A4 (en) 2022-04-27
WO2020033742A1 (en) 2020-02-13
US12246063B2 (en) 2025-03-11
US20250195636A1 (en) 2025-06-19
US20210268096A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
Rigter et al. A protective and safe intranasal RSV vaccine based on a recombinant prefusion-like form of the F protein bound to bacterium-like particles
US20240067706A1 (en) Fully human broad-spectrum neutralizing antibody 76e1 against coronavirus, and use thereof
Stepanova et al. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes
US20240400651A1 (en) Neutralizing monoclonal antibodies against covid-19
US11723977B2 (en) Broadly neutralizing antibodies directed against the rabies virus glycoprotein and uses thereof
CN111228483A (zh) 用于新型冠状病毒和非典病毒的广谱抗体喷剂
RU2764740C1 (ru) Биспецифическое антитело против вируса бешенства и его применение
TW202221024A (zh) 結合sars-cov-2 s蛋白之中和抗體
KR20100091195A (ko) 항ｒｓｖ ｇ 단백질 항체
Rainho-Tomko et al. Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle
US20240150414A1 (en) Conformational epitopes in respiratory syncytial virus g protein central conserved region
KR20090088871A (ko) 인간 메타뉴모바이러스를 중화시키는 인간 항체
JP2026062799A (ja) 重症急性呼吸器症候群コロナウイルス２（ｓａｒｓ－ｃｏｖ－２）ポリペプチドおよびワクチン目的でのその使用
Naidoo et al. The potential of nanobodies for COVID-19 diagnostics and therapeutics
TWI869137B (zh) 廣譜新型冠狀病毒的雙特異性抗體
KR20220166819A (ko) 예방 및 치료에서의 천연 항체
US12246063B2 (en) Immunogen providing an extended protective lifetime against respiratory syncytial virus (RSV) and vaccines thereof
JP2024540505A (ja) ユニバーサルサルベコウイルスワクチン
JP2024502783A (ja) コロナウイルスワクチン
Muhammed et al. Breakthroughs in SARS-CoV-2-monoclonal antibodies development
KR20260047586A (ko) 인플루엔자 b 바이러스에 대한 광범위 반응성 항체
CN121652268A (zh) 一种基孔肯雅病毒包膜e2蛋白单克隆抗体及其用途
CN121426940A (zh) 特异性结合呼吸道合胞病毒的抗体及其应用
Seedarnee A Monoclonal Antibody Targeting Matrix Protein M1 of Influenza A Virus, identifies an Epitope as a Potential Immunogen for a Universal Influenza A Virus Vaccine Component
Fedechkin Structures Of Respiratory Syncytial Virus G Antigen Bound To Broadly Neutralizing Antibodies For Vaccine And Therapeutic Design